Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Weight gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with serious mental illness: a subgroup analysis of a randomized trial.

Thorndike AN, Achtyes ED, Cather C, Pratt S, Pachas GN, Hoeppner SS, Evins AE.

J Clin Psychiatry. 2016 Mar;77(3):e320-6. doi: 10.4088/JCP.15m10074.

PMID:
27046320
2.

Effective Cessation Strategies for Smokers with Schizophrenia.

Evins AE, Cather C.

Int Rev Neurobiol. 2015;124:133-47. doi: 10.1016/bs.irn.2015.08.001. Epub 2015 Sep 14.

PMID:
26472528
3.

The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components.

Mueser KT, Penn DL, Addington J, Brunette MF, Gingerich S, Glynn SM, Lynde DW, Gottlieb JD, Meyer-Kalos P, McGurk SR, Cather C, Saade S, Robinson DG, Schooler NR, Rosenheck RA, Kane JM.

Psychiatr Serv. 2015 Jul;66(7):680-90. doi: 10.1176/appi.ps.201400413. Epub 2015 Mar 16.

PMID:
25772766
4.

Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices.

Evins AE, Cather C, Laffer A.

Harv Rev Psychiatry. 2015 Mar-Apr;23(2):90-8. doi: 10.1097/HRP.0000000000000063. Review.

5.

A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.

Vincenzi B, Stock S, Borba CP, Cleary SM, Oppenheim CE, Petruzzi LJ, Fan X, Copeland PM, Freudenreich O, Cather C, Henderson DC.

Schizophr Res. 2014 Nov;159(2-3):395-403. doi: 10.1016/j.schres.2014.08.021. Epub 2014 Sep 26.

6.

Evolving illness, shifting perspectives: childhood psychosis through the lenses of family therapy and individual therapy.

Greene DI, Spencer AE, Pridgen BC, Cather C, Ablon S.

Harv Rev Psychiatry. 2013 Sep-Oct;21(5):259-68. doi: 10.1097/HRP.0b013e3182a75c7a. No abstract available.

PMID:
24651558
7.

Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.

Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, Goff DC, Achtyes ED, Ayer D, Schoenfeld DA.

JAMA. 2014 Jan 8;311(2):145-54. doi: 10.1001/jama.2013.285113.

8.

Long-term outcomes of a randomized trial of integrated skills training and preventive healthcare for older adults with serious mental illness.

Bartels SJ, Pratt SI, Mueser KT, Forester BP, Wolfe R, Cather C, Xie H, McHugo GJ, Bird B, Aschbrenner KA, Naslund JA, Feldman J.

Am J Geriatr Psychiatry. 2014 Nov;22(11):1251-61. doi: 10.1016/j.jagp.2013.04.013. Epub 2013 Aug 14.

9.

An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia.

Cather C, Dyer MA, Burrell HA, Hoeppner B, Goff DC, Evins AE.

J Dual Diagn. 2013;9(1):87-93.

10.

Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial.

Pachas GN, Cather C, Pratt SA, Hoeppner B, Nino J, Carlini SV, Achtyes ED, Lando H, Mueser KT, Rigotti NA, Goff DC, Evins AE.

J Dual Diagn. 2012;8(2):117-125. Epub 2012 May 11.

11.

D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia.

Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, Goff DC.

Schizophr Res. 2011 Sep;131(1-3):69-74. doi: 10.1016/j.schres.2011.05.029. Epub 2011 Jun 30.

12.

Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia.

Henderson DC, Freudenreich O, Borba CP, Wang X, Copeland PM, Macklin E, Fan X, Cather C, Goff DC.

Schizophr Res. 2011 Aug;130(1-3):53-6. doi: 10.1016/j.schres.2011.04.009. Epub 2011 May 11.

PMID:
21565464
13.

Neurocognition and social skill in older persons with schizophrenia and major mood disorders: An analysis of gender and diagnosis effects.

Mueser KT, Pratt SI, Bartels SJ, Forester B, Wolfe R, Cather C.

J Neurolinguistics. 2010 May;23(3):297-317.

14.

Morgellons disease, or antipsychotic-responsive delusional parasitosis, in an HIV patient: beliefs in the age of the Internet.

Freudenreich O, Kontos N, Tranulis C, Cather C.

Psychosomatics. 2010 Nov-Dec;51(6):453-7. doi: 10.1176/appi.psy.51.6.453. No abstract available.

PMID:
21051675
15.

Randomized trial of social rehabilitation and integrated health care for older people with severe mental illness.

Mueser KT, Pratt SI, Bartels SJ, Swain K, Forester B, Cather C, Feldman J.

J Consult Clin Psychol. 2010 Aug;78(4):561-73. doi: 10.1037/a0019629.

16.

Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone.

Henderson DC, Sharma B, Fan X, Copeland PM, Borba CP, Freudenreich O, Cather C, Evins AE, Goff DC.

Ann Clin Psychiatry. 2010 Feb;22(1):33-42.

PMID:
20196981
17.

Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.

Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Freudenreich O, Cather C, Evins AE, Goff DC.

J Psychiatr Pract. 2009 Jul;15(4):251-61. doi: 10.1097/01.pra.0000358312.99233.ef.

18.

Cognitive behavioral therapy of negative symptoms.

Perivoliotis D, Cather C.

J Clin Psychol. 2009 Aug;65(8):815-30. doi: 10.1002/jclp.20614.

PMID:
19572278
19.

Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC.

J Clin Psychopharmacol. 2009 Apr;29(2):165-9. doi: 10.1097/JCP.0b013e31819a8dbe.

20.

Family intervention for co-occurring substance use and severe psychiatric disorders: participant characteristics and correlates of initial engagement and more extended exposure in a randomized controlled trial.

Mueser KT, Glynn SM, Cather C, Zarate R, Fox L, Feldman J, Wolfe R, Clark RE.

Addict Behav. 2009 Oct;34(10):867-77. doi: 10.1016/j.addbeh.2009.03.025. Epub 2009 Apr 1.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk